Search

Your search keyword '"Cohen, Alexander T."' showing total 1,017 results
Start Over Author "Cohen, Alexander T."
1,017 results on '"Cohen, Alexander T."'

1. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study

Author

Linder, Marie, Ekbom, Anders, Brobert, Gunnar, Vogtländer, Kai, Balabanova, Yanina, Becattini, Cecilia, Carrier, Marc, Cohen, Alexander T., Coleman, Craig I., Khorana, Alok A., Lee, Agnes Y. Y., Psaroudakis, George, Abdelgawwad, Khaled, Rivera, Marcela, Schaefer, Bernhard, and Giunta, Diego Hernan

Published
2024
Full Text
View/download PDF

2. Undertaking multi-centre randomised controlled trials in primary care: learnings and recommendations from the PULsE-AI trial researchers

Author

Pollock, Kevin G., Dickerson, Carissa, Kainth, Manjit, Lawton, Sarah, Hurst, Michael, Sugrue, Daniel M., Arden, Chris, Davies, D. Wyn, Martin, Anne-Céline, Sandler, Belinda, Gordon, Jason, Farooqui, Usman, Clifton, David, Mallen, Christian, Rogers, Jennifer, Hill, Nathan R., Camm, A. John, and Cohen, Alexander T.

Published
2024
Full Text
View/download PDF

13. Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation

Author

Gwozdz, Adam M, de Jong, Cindy M M, Fialho, Luz Sousa, Likitabhorn, Theerawich, Sossi, Frieda, Jaber, Paula Blancarte, Højen, Anette Arbjerg, Arcelus, Juan I, Auger, William R, Ay, Cihan, Barco, Stefano, Gazzana, Marcelo B, Bayley, Julie, Bertoletti, Laurent, Cate-Hoek, Arina ten, Cohen, Alexander T, Connors, Jean M, Galanaud, Jean-Philippe, Labropoulos, Nicos, Langlois, Nicole, Meissner, Mark H, Noble, Simon, Nossent, Esther J, de León Lovatón, Paula Ponce, Robert-Ebadi, Helia, Rosovsky, Rachel P, Smolenaars, Noa, Toshner, Mark, Tromeur, Cécile, Wang, Kang-Ling, Westerlund, Eli, de Wit, Kerstin, Black, Stephen A, and Klok, Frederikus A

Published
2022
Full Text
View/download PDF

15. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Author

Milling, Truman J., Jr, Middeldorp, Saskia, Xu, Lizhen, Koch, Bruce, Demchuk, Andrew, Eikelboom, John W., Verhamme, Peter, Cohen, Alexander T., Beyer-Westendorf, Jan, Michael Gibson, C., Lopez-Sendon, Jose, Crowther, Mark, Shoamanesh, Ashkan, Coppens, Michiel, Schmidt, Jeannot, Albaladejo, Pierre, Connolly, Stuart J., Anand, R., Bastani, A., Clark, C., Concha, M., Cornell, J., Dombrowski, K., Fermann, G., Fulmer, J., Goldstein, J., Kereiakes, D., Milling, T., Pallin, D., Patel, N., Refaai, M., Rehman, M., Schmaier, A., Schwarz, E., Shillinglaw, W., Spohn, M., Takata, T., Venkat, A., Welker, J., Welsby, I., Wilson, J., Van Keer, L., Verschuren, F., Blostein, M., Eikelboom, J., Althaus, K., Berrouschot, J., Braun, G., Doeppner, T., Dziewas, R., Genth-Zotz, S., Greinacher, P., Hamann, F., Hanses, F., Heide, W., Kallmuenzer, B., Kermer, P., Poli, S., Royl, G., Schellong, S., Schnupp, S., Schwarze, J., Spies, C., Thomalla, G., von Mering, M., Weissenborn, K., Wollenweber, F., Gumbinger, C., Jaschinski, U., Maschke, M., Mochmann, H-C., Pfeilschifter, W., Pohlmann, C., Zahn, R., Bouzat, P., Schmidt, J., Vallejo, C., Floccard, B., Coppens, M., van Wissen, S., Arellano-Rodrigo, E., Valles, E., Alikhan, R., Breen, K., Hall, R., Crowther, M., Albaladejo, P., Cohen, A., Demchuk, A.M., Schmidt, J., Wyse, D.G., Garcia, D.A., Prins, M., Nakamya, J., Büller, H.R., Mahaffey, K. W., Alexander, J. H., Cairns, J.A., Hart, R.G., Joyner, C.D., Raskob, G.E., Schulman, S., Veltkamp, R., Meeks, B., Zotova, E., Ahmad, S., Pinto, T., Baker, K., Dykstra, A., Holadyk-Gris, I., Malvaso, A., and Demchuk, A.M.

Published
2023
Full Text
View/download PDF

21. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database

Author

Barco, Stefano, Valerio, Luca, Ageno, Walter, Cohen, Alexander T, Goldhaber, Samuel Z, Hunt, Beverley J, Iorio, Alfonso, Jimenez, David, Klok, Frederikus A, Kucher, Nils, Mahmoudpour, Seyed Hamidreza, Middeldorp, Saskia, Münzel, Thomas, Tagalakis, Vicky, Wendelboe, Aaron M, and Konstantinides, Stavros V

Published
2021
Full Text
View/download PDF

22. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts

Author

Bazarbashi,Shouki, El Zawahry,Heba, Owaidah,Tarek, AlBader,Mohammad, Warsi,Ashraf, Marashi,Mahmoud, Dawoud,Emad, Jaafar,Hassan, Sholkamy,Sherif, Haddad,Fady, Cohen,Alexander T, Bazarbashi,Shouki, El Zawahry,Heba, Owaidah,Tarek, AlBader,Mohammad, Warsi,Ashraf, Marashi,Mahmoud, Dawoud,Emad, Jaafar,Hassan, Sholkamy,Sherif, Haddad,Fady, and Cohen,Alexander T

Abstract

Shouki Bazarbashi,1 Heba Mohamed El Zawahry,2 Tarek Owaidah,3 Mohammad A AlBader,4 Ashraf Warsi,5– 7 Mahmoud Marashi,8,9 Emad Dawoud,10 Hassan Jaafar,11 Sherif M Sholkamy,12 Fady Haddad,13 Alexander T Cohen14 1Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia; 2Department of Medical Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt; 3Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia; 4Hematology Unit, Al Sabah Hospital, South Surra, Kuwait; 5Department of Adult Hematology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs–Western Region, Jeddah, Saudi Arabia; 6College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs–Western Region, Jeddah, Saudi Arabia; 7King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs-Western Region, Jeddah, Saudi Arabia; 8Hematology Department, Dubai Hospital, Dubai, United Arab Emirates; 9Department of Hematology, Mediclinic City Hospital, Dubai, United Arab Emirates; 10Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates; 11Department of Oncology, Sheikh Khalifa Specialty Hospital, Ras Al-Khaimah, United Arab Emirates; 12Department of Vascular Surgery, Ain Shams University, Cairo, Egypt; 13Vascular and Endovascular Surgery, American University of Beirut Medical Center, Beirut, Lebanon; 14Department of Haematological Medicine, Guy’s and St Thomas’ Hospitals NHS Foundation Trust, King’s College London, London, UKCorrespondence: Shouki Bazarbashi, Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Alfaisal University, 1 Alzahrawi Street, Riyadh, 11211, Saudi Arabia, Tel +966 505443546, Email bazarbashi@gmail.com

Published
2024

23. ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries

Author

Cohen, Alexander T., Hoffmann, Ulrich, Hainaut, Philippe, Gaine, Sean, Ay, Cihan, Coppens, Michiel, Schindewolf, Marc, Jimenez, David, Brüggenjürgen, Bernd, Levy, Pierre, Laeis, Petra, Fronk, Eva-Maria, Zierhut, Wolfgang, Malzer, Thomas, Manu, Marius Constantin, Reimitz, Paul-Egbert, Bramlage, Peter, and Agnelli, Giancarlo

Published
2020
Full Text
View/download PDF

29. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

Author

Connolly, Stuart J, Milling, Truman J, Eikelboom, John W, Gibson, C Michael, Curnutte, John T, Gold, Alex, Bronson, Michele D, Lu, Genmin, Conley, Pamela B, Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T, Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Goodman, Shelly, Leeds, Janet, Wiens, Brian L, Siegal, Deborah M, Zotova, Elena, Meeks, Brandi, Nakamya, Juliet, Lim, W Ting, and Crowther, Mark

Subjects
Hematology, Clinical Research, Cardiovascular, Acute Disease, Aged, Aged, 80 and over, Cardiovascular Diseases, Enoxaparin, Factor Xa, Factor Xa Inhibitors, Female, Gastrointestinal Hemorrhage, Hemorrhage, Humans, Infusions, Intravenous, Intracranial Hemorrhages, Male, Prospective Studies, Pyrazoles, Pyridones, Recombinant Proteins, Rivaroxaban, Thrombosis, ANNEXA-4 Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundAndexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers.MethodsIn this multicenter, prospective, open-label, single-group study, we evaluated 67 patients who had acute major bleeding within 18 hours after the administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a 2-hour infusion of the drug. Patients were evaluated for changes in measures of anti-factor Xa activity and were assessed for clinical hemostatic efficacy during a 12-hour period. All the patients were subsequently followed for 30 days. The efficacy population of 47 patients had a baseline value for anti-factor Xa activity of at least 75 ng per milliliter (or ≥0.5 IU per milliliter for those receiving enoxaparin) and had confirmed bleeding severity at adjudication.ResultsThe mean age of the patients was 77 years; most of the patients had substantial cardiovascular disease. Bleeding was predominantly gastrointestinal or intracranial. The mean (±SD) time from emergency department presentation to the administration of the andexanet bolus was 4.8±1.8 hours. After the bolus administration, the median anti-factor Xa activity decreased by 89% (95% confidence interval [CI], 58 to 94) from baseline among patients receiving rivaroxaban and by 93% (95% CI, 87 to 94) among patients receiving apixaban. These levels remained similar during the 2-hour infusion. Four hours after the end of the infusion, there was a relative decrease from baseline of 39% in the measure of anti-factor Xa activity among patients receiving rivaroxaban and of 30% among those receiving apixaban. Twelve hours after the andexanet infusion, clinical hemostasis was adjudicated as excellent or good in 37 of 47 patients in the efficacy analysis (79%; 95% CI, 64 to 89). Thrombotic events occurred in 12 of 67 patients (18%) during the 30-day follow-up.ConclusionsOn the basis of a descriptive preliminary analysis, an initial bolus and subsequent 2-hour infusion of andexanet substantially reduced anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors, with effective hemostasis occurring in 79%. (Funded by Portola Pharmaceuticals; ANNEXA-4 ClinicalTrials.gov number, NCT02329327 .).

Published
2016

34. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.

Author

Bazarbashi, Shouki, El Zawahry, Heba Mohamed, Owaidah, Tarek, AlBader, Mohammad A, Warsi, Ashraf, Marashi, Mahmoud, Dawoud, Emad, Jaafar, Hassan, Sholkamy, Sherif M, Haddad, Fady, and Cohen, Alexander T

Subjects
ORAL medication, GASTROINTESTINAL hemorrhage, THROMBOEMBOLISM, ANTICOAGULANTS, THROMBOSIS, LOW-molecular-weight heparin
Abstract

Venous thromboembolism is a leading cause of morbidity and mortality in patients with active cancer who require anticoagulation treatment. Choice of anticoagulant is based on careful balancing of the risks and benefits of available classes of treatment: vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs). Results from randomized controlled trials have shown the consistent efficacy of DOACs versus LMWH in the treatment of cancer-associated venous thromboembolism (VTE). However, increased major gastrointestinal bleeding was observed for edoxaban and rivaroxaban, but not apixaban, compared with LMWH dalteparin. Most guidelines recommend DOACs for the treatment of cancer-associated VTE in patients without gastrointestinal or genitourinary cancer, and with considerations for renal impairment and drug–drug interactions. These updates represent a major paradigm shift for clinicians in the Middle East and North Africa. The decision to prescribe a DOAC for a patient with cancer is not always straightforward, particularly in challenging subgroups of patients with an increased risk of bleeding. In patients with gastrointestinal malignancies who are at high risk of major gastrointestinal bleeds, apixaban may be the preferred DOAC; however, caution should be exercised if patients have upper or unresected lower gastrointestinal tumors. In patients with gastrointestinal malignancies and upper or unresected lower gastrointestinal tumors, LMWH may be preferred. Vitamin K antagonists should be used only when DOACs and LMWH are unavailable or unsuitable. In this review, we discuss the overall evidence for DOACs in the treatment of cancer-associated VTE and provide treatment suggestions for challenging subgroups of patients with cancer associated VTE. Plain Language Summary: Patients with cancer are at risk of blood clots forming in their veins, which can cause illness and death. To prevent such blood clots, most patients with cancer need anticoagulant therapy. There are three types of anticoagulants available for the treatment of cancer-associated blood clots in a vein, namely, vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs). Drug trials have shown that DOACs are more effective than LMWH; however, DOACs can have a greater risk of causing major gastrointestinal bleeding. Among DOACs, edoxaban and rivaroxaban are drugs associated with higher rates of gastrointestinal bleeding. Recently updated guidelines for doctors recommend that DOACs be used as the first treatment for patients with cancer at risk of blood clot formation in a vein. For doctors in the Middle East and North Africa, this new approach differs from existing practices. Notably, choosing a treatment also depends on the type of cancer, because gastrointestinal cancers and cancers of the genitals and urinary system have an especially high risk of gastrointestinal bleeding. The choice also depends on the presence of kidney problems, drug–drug interactions, and access to the drugs. Apixaban may be the preferred DOAC in patients with gastrointestinal cancer, but this drug should be used with care in patients with upper or unresected lower gastrointestinal tumors. For patients with upper or unresected lower gastrointestinal tumors, treatment with LMWH may be preferred. Vitamin K antagonists should be used only when DOACs and LMWH are unavailable or unsuitable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease.

Author

Cohen, Alexander T., Noxon, Virginia, Dhamane, Amol D., Shah, Shrushti, Hines, Dionne M., Alfred, Tamuno, Chaves, José, and Luo, Xuemei

Subjects
*KIDNEY diseases, *THROMBOEMBOLISM, *LOW-molecular-weight heparin, *PROPORTIONAL hazards models, *ANTICOAGULANTS
Abstract

Patients with active cancer and venous thromboembolism (VTE) have elevated risk of recurrent VTE (rVTE) and major bleeding (MB). The risk is even higher within those with a prior bleeding event or renal disease. There is a need to understand the risk of rVTE and MB of commonly used anticoagulants among these high-risk patients. VTE patients with active cancer and treated with apixaban, warfarin, or low molecular weight heparin (LMWH) within 30 days of VTE were identified from five claims databases in the United States. Inverse probability of treatment weighting (IPTW) was used to balance patient characteristics. The post-IPTW population was stratified by prior bleed or renal disease status. Cox proportional hazards models were used to evaluate interactions between treatment and prior bleed or renal disease on risk of rVTE and MB, with p value <.1 considered significant. Study criteria were met by 30,586 VTE cancer patients: 35.0% had prior bleed and 29.0% had renal disease. For apixaban, LMWH, and warfarin cohorts, the incidence (events per 100 person-years) of MB was higher in patients with prior bleed (17.48 vs 7.58, 25.61 vs 13.11, and 20.38 vs 8.97) or renal disease (15.79 vs 8.71, 22.11 vs 15.90, and 18.49 vs 10.39) vs those without the conditions. Generally, there were no significant interactions between anticoagulant use and prior bleed or renal disease on rVTE and MB (p for interaction >.1). The incidence of MB was higher among those with prior bleed or renal disease. Effects of apixaban, warfarin, or LMWH were generally consistent regardless of prior bleed or renal disease status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Event rates and risk factors for venous thromboembolism and major bleeding in a population of hospitalized adult patients with acute medical illness receiving enoxaparin thromboprophylaxis

Author

Gal, Grégoire Le, primary, Agnelli, Giancarlo, additional, Darius, Harald, additional, Kahn, Susan R, additional, Owaidah, Tarek, additional, Rocha, Ana Thereza, additional, Zhai, Zhenguo, additional, Khan, Irfan, additional, Djoudi, Yasmina, additional, Ponomareva, Ekaterina, additional, and Cohen, Alexander T., additional

Published
2023
Full Text
View/download PDF

38. Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel

Author

Fermann, Gregory J., primary, Cash, Brooks D., additional, Coelho‐Prabhu, Nayantara, additional, Maegele, Marc, additional, Bingisser, Roland, additional, Sehgal, Vinay, additional, Cohen, Alexander T., additional, Golden, Anna Hundt, additional, Russo, Jon, additional, Price, Mark, additional, Mangel, Allen, additional, Koch, Bruce, additional, Christoph, Mary J., additional, and Milling, Truman J., additional

Published
2023
Full Text
View/download PDF

39. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy

Author

Chi, Gerald, Gibson, C. Michael, Kalayci, Arzu, Cohen, Alexander T., Hernandez, Adrian F., Hull, Russell D., and Kahe, Farima

Subjects
Bristol-Myers Squibb Co., Boehringer Ingelheim GmbH, Medical research -- Comparative analysis -- Health aspects, Medicine, Experimental -- Comparative analysis -- Health aspects, Mortality -- Canada, Thromboembolism -- Drug therapy, Hospital patients -- Drug therapy, Health care industry
Abstract

Purpose To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients. Methods The APEX trial randomized 7513 acutely ill hospitalized patients to betrixaban for 35-42 days or enoxaparin for 10 ± 4 days. Among those, 703 critically ill patients admitted to the intensive care unit were included in the analysis, and 547 patients who had no severe renal insufficiency or P-glycoprotein inhibitor use were included in the full-dose stratum. The risk of VTE, bleeding, net clinical benefit (composite of VTE and major bleeding), and mortality was compared at 35-42 days and at 77 days. Results At 35-42 days, extended betrixaban reduced the risk of VTE (4.27% vs 7.95%, P = 0.042) without causing excess major bleeding (1.14% vs 3.13%, P = 0.07). Both VTE (3.32% vs 8.33%, P = 0.013) and major bleeding (0.00% vs 3.26%, P = 0.003) were decreased in the full-dose stratum. Patients who received betrixaban had more non-major bleeding than enoxaparin (overall population: 2.56% vs 0.28%, P = 0.011; full-dose stratum: 3.32% vs 0.36%, P = 0.010). Mortality was similar at the end of study (overall population: 13.39% vs 16.19%, P = 0.30; full-dose stratum: 13.65% vs 16.30%, P = 0.39). Conclusions Compared with shorter-duration enoxaparin, critically ill medical patients who received extended-duration betrixaban had fewer VTE without more major bleeding events. The benefit of betrixaban was driven by preventing asymptomatic thrombosis and offset by an elevated risk of non-major bleeding. The APEX trial did not stratify by intensive care unit admission and the present study included a highly selected population of critically ill patients. These hypothesis-generating findings need to be validated in future studies. Clinical trial registration http://www.clinicaltrials.gov. Unique identifier: NCT01583218., Author(s): Gerald Chi [sup.1], C. Michael Gibson [sup.2], Arzu Kalayci [sup.1], Alexander T. Cohen [sup.3], Adrian F. Hernandez [sup.4], Russell D. Hull [sup.5], Farima Kahe [sup.1], Mehrian Jafarizade [sup.1], Sadaf [...]

Published
2019
Full Text
View/download PDF

44. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis

Author

MS Interne Geneeskunde, Cardiovasculaire Epi Team 7B, Epi Infectieziekten, Circulatory Health, Medische Staf Spoedeisende Hulp, de Winter, Maria A., Uijl, Alicia, Büller, Harry R., Carrier, Marc, Cohen, Alexander T., Hansen, John Bjarne, Kaasjager, Karin H.A.H., Kakkar, Ajay K., Middeldorp, Saskia, Raskob, Gary E., Sørensen, Henrik Toft, Wells, Philip S., Nijkeuter, Mathilde, Dorresteijn, Jannick A.N., MS Interne Geneeskunde, Cardiovasculaire Epi Team 7B, Epi Infectieziekten, Circulatory Health, Medische Staf Spoedeisende Hulp, de Winter, Maria A., Uijl, Alicia, Büller, Harry R., Carrier, Marc, Cohen, Alexander T., Hansen, John Bjarne, Kaasjager, Karin H.A.H., Kakkar, Ajay K., Middeldorp, Saskia, Raskob, Gary E., Sørensen, Henrik Toft, Wells, Philip S., Nijkeuter, Mathilde, and Dorresteijn, Jannick A.N.

Published
2023

45. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score

Author

MS Interne Geneeskunde, Epi Infectieziekten, Circulatory Health, Interne Geneeskunde Vasculaire, Medische Staf Spoedeisende Hulp, De Winter, Maria A., Büller, Harry R., Carrier, Marc, Cohen, Alexander T., Hansen, John Bjarne, Kaasjager, Karin A.H., Kakkar, Ajay K., Middeldorp, Saskia, Raskob, Gary E., Sørensen, Henrik T., Visseren, Frank L.J., Wells, Philip S., Dorresteijn, Jannick A.N., Nijkeuter, Mathilde, Braekkan, Sigrid K., Burggraaf, Louise, Cannegieter, Suzanne C., Farjat, Alfredo, Pap, Akos Ferenc, Goldhaber, Samuel, Grosso, Michael, Horváth-Puhó, Erzsebet, Lensing, Anthonie W.A., Pieper, Karen, Schulman, Sam, Shi, Minggao, Virdone, Saverio, MS Interne Geneeskunde, Epi Infectieziekten, Circulatory Health, Interne Geneeskunde Vasculaire, Medische Staf Spoedeisende Hulp, De Winter, Maria A., Büller, Harry R., Carrier, Marc, Cohen, Alexander T., Hansen, John Bjarne, Kaasjager, Karin A.H., Kakkar, Ajay K., Middeldorp, Saskia, Raskob, Gary E., Sørensen, Henrik T., Visseren, Frank L.J., Wells, Philip S., Dorresteijn, Jannick A.N., Nijkeuter, Mathilde, Braekkan, Sigrid K., Burggraaf, Louise, Cannegieter, Suzanne C., Farjat, Alfredo, Pap, Akos Ferenc, Goldhaber, Samuel, Grosso, Michael, Horváth-Puhó, Erzsebet, Lensing, Anthonie W.A., Pieper, Karen, Schulman, Sam, Shi, Minggao, and Virdone, Saverio

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results